Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies
US10272112B2 · kind B2 · utility
1Cited by
6References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 27, 2017 |
| Grant date | Apr 30, 2019 |
| Priority date | — |
| Expiry date | Jun 27, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2501/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to tolerogenic mammalian dendritic cells (iDCs) and methods for the production of tolerogenic DCs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects. Enhanced tolerogenicity in a host can be useful for treating inflammatory and autoimmune related diseases, such as type 1 diabetes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.